{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:27:28Z","timestamp":1793374048071,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["21-Y17"],"award-info":[{"award-number":["21-Y17"]}],"id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.biopha.2023.114252","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T17:01:35Z","timestamp":1673629295000},"page":"114252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"special_numbering":"C","title":["Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation"],"prefix":"10.1016","volume":"159","author":[{"given":"Qichao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114252_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","article-title":"Type 2 diabetes mellitus in older adults: clinical considerations and management","volume":"17","author":"Bellary","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2023.114252_bib2","first-page":"139","article-title":"Highlighting diabetes \u2013 the epidemic continues","volume":"176","author":"Schmidt","year":"2016","journal-title":"Physiol. Behav."},{"issue":"2021","key":"10.1016\/j.biopha.2023.114252_bib3","article-title":"Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment","author":"Samsu","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2023.114252_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2023.114252_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.dsx.2018.11.054","article-title":"Diabetic nephropathy: an update on pathogenesis and drug development","volume":"13","author":"A\/L B Vasanth Rao","year":"2019","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"10.1016\/j.biopha.2023.114252_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/10408363.2017.1377682","article-title":"Biomarkers of diabetic nephropathy: a 2017 update","volume":"54","author":"Papadopoulou-Marketou","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.biopha.2023.114252_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-018-0791-8","article-title":"Efficacy of low-protein diet for diabetic nephropathy: a systematic review of randomized controlled trials","volume":"17","author":"Zhu","year":"2018","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.biopha.2023.114252_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-1007-6","article-title":"Efficacy of low-protein diet in diabetic nephropathy: a meta-analysis of randomized controlled trials","volume":"18","author":"Li","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.biopha.2023.114252_bib9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11255-020-02717-2","article-title":"Low-salt low-protein diet and blood pressure control in patients with advanced diabetic kidney disease and heavy proteinuria","volume":"53","author":"Mihalache","year":"2021","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/nep.13152","article-title":"Cyclic and intermittent very low-protein diet can have beneficial effects against advanced diabetic nephropathy in Wistar fatty (fa\/fa) rats, an animal model of type 2 diabetes and obesity","volume":"22","author":"Kitada","year":"2017","journal-title":"Nephrology"},{"key":"10.1016\/j.biopha.2023.114252_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0184789","article-title":"Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial","volume":"12","author":"Yacoub","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114252_bib12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/mnfr.201300847","article-title":"Maillard reaction products modulate gut microbiota composition in adolescents","volume":"58","author":"Seiquer","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.biopha.2023.114252_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-0043-100117","article-title":"Effect of carnosine on renal function, oxidation and glycation products in the kidneys of high-fat diet\/streptozotocin-induced diabetic rats","volume":"125","author":"Fatih Aydln","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.biopha.2023.114252_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semnephrol.2007.01.009","article-title":"The renin-angiotensin system and diabetic nephropathy","volume":"27","author":"Gurley","year":"2007","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106081","article-title":"ACE inhibitor-mediated angioedema","volume":"78","author":"Montinaro","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2023.114252_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jcjd.2015.08.016","article-title":"The role of renin angiotensin aldosterone system genes in diabetic nephropathy","volume":"40","author":"Rahimi","year":"2016","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.biopha.2023.114252_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib19","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1161\/01.CIR.88.6.2849","article-title":"Identification of functional angiotensin II receptors on rat cardiac fibroblasts","volume":"88","author":"Villarreal","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.114252_bib20","article-title":"Cardiac hypertrophy-induced changes in mRNA levels for TGF-\u03b21, fibronectin, and collagen","volume":"262","author":"Villarreal","year":"1992","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.biopha.2023.114252_bib21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/hr.2011.16","article-title":"Aldosterone\/NaCl-induced renal and cardiac fibrosis is modulated by TGF-\u0392 responsiveness of T cells","volume":"34","author":"Schreier","year":"2011","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2023.114252_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2018.06.001","article-title":"AGE-RAGE axis blockade in diabetic nephropathy: current status and future directions","volume":"833","author":"Sanajou","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114252_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.ASN.0000077414.59717.74","article-title":"The AGE-RAGE system and diabetic nephropathy","volume":"14","author":"Sakurai","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib24","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.2174\/092986710793348581","article-title":"Oxidative stress in diabetic nephropathy","volume":"17","author":"Kashihara","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2023.114252_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-36344-w","article-title":"AKF-PD alleviates diabetic nephropathy via blocking the RAGE\/AGEs\/NOX and PKC\/NOX Pathways","volume":"9","author":"Qin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.114252_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.freeradbiomed.2007.03.027","article-title":"Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy","volume":"43","author":"Lambeth","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12672-018-0342-9","article-title":"RAGE and its ligands: molecular interplay between glycation, inflammation, and hallmarks of cancer\u2014a review","volume":"9","author":"Palanissami","year":"2018","journal-title":"Horm. Cancer"},{"key":"10.1016\/j.biopha.2023.114252_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174121","article-title":"JAK\/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes","volume":"902","author":"Chen","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114252_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5582\/bst.2018.01255","article-title":"Danzhi Jiangtang Capsule ameliorates kidney injury via inhibition of the JAK-STAT signaling pathway and increased antioxidant capacity in STZ-induced diabetic nephropathy rats","volume":"12","author":"Sun","year":"2018","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2023.114252_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vph.2005.08.021","article-title":"JANUS under stress - role of JAK\/STAT signaling pathway in vascular diseases","volume":"43","author":"Grote","year":"2005","journal-title":"Vasc. Pharmacol."},{"issue":"2020)","key":"10.1016\/j.biopha.2023.114252_bib31","article-title":"Unveiling the role of inflammation and oxidative stress on age-related cardiovascular diseases","author":"De Almeida","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2023.114252_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112170","article-title":"MAPK \/ERK signaling pathway: a potential target for the treatment of intervertebral disc degeneration","volume":"143","author":"Zhang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.114252_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-019-1177-1","article-title":"Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte","volume":"10","author":"Jin","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biopha.2023.114252_bib34","first-page":"1","article-title":"Galangin protects against oxidative damage and attenuates inflammation and apoptosis via modulation of nf-\u03bab p65 and caspase-3 signaling molecules in a rat model of diabetic nephropathy","volume":"72","author":"Aladaileh","year":"2021","journal-title":"J. Physiol. Pharm."},{"key":"10.1016\/j.biopha.2023.114252_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/nu12051516","article-title":"Punicalagin protects diabetic nephropathy by inhibiting pyroptosis based on TXNIP\/NLRP3 pathway","volume":"12","author":"An","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2023.114252_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112293","article-title":"Endoplasmic reticulum stress related factor IRE1\u03b1 regulates TXNIP\/NLRP3-mediated pyroptosis in diabetic nephropathy","volume":"396","author":"Ke","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2023.114252_bib37","first-page":"1","article-title":"Relevance of the pyroptosis-related inflammasome pathway in the pathogenesis of diabetic kidney disease","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.114252_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061447","article-title":"4\u2032-methoxyresveratrol alleviated AGE-induced inflammation via RAGE-mediated NF-\u03baB and NLRP3 inflammasome pathway","volume":"23","author":"Yu","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.114252_bib39","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1161\/ATVBAHA.115.307312","article-title":"P38\u03b4 MAPK: a novel regulator of NLRP3 inflammasome activation with increased expression in coronary atherogenesis","volume":"36","author":"Rajam\u00e4ki","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2023.114252_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0084588","article-title":"Nitrosative\/oxidative stress conditions regulate Thioredoxin-Interacting Protein (TXNIP) expression and thioredoxin-1 (TRX-1) nuclear localization","volume":"8","author":"Ogata","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114252_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2019.00603","article-title":"TLR4\/NF-\u03baB signaling induces GSDMD-related pyroptosis in tubular cells in diabetic kidney disease","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.biopha.2023.114252_bib42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.bbrc.2018.09.037","article-title":"ERp44 depletion exacerbates ER stress and aggravates diabetic nephropathy in db\/db mice","volume":"504","author":"Pang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2023.114252_bib43","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1128\/MCB.01445-09","article-title":"Nox4-derived H 2 O 2 mediates endoplasmic reticulum signaling through local ras activation","volume":"30","author":"Wu","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2023.114252_bib44","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1152\/ajprenal.00021.2011","article-title":"The endoplasmic reticulum stress response and diabetic kidney disease","volume":"300","author":"Cunard","year":"2011","journal-title":"Am. J. Physiol. - Ren. Physiol."},{"key":"10.1016\/j.biopha.2023.114252_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/187152910791292529","article-title":"Diabetes, hyperglycemia and accelerated atherosclerosis: evidence supporting a role for endoplasmic reticulum (ER) stress signaling","volume":"10","author":"McAlpine","year":"2012","journal-title":"Cardiovasc. Hematol. Disord. Targets"},{"key":"10.1016\/j.biopha.2023.114252_bib46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1681\/ASN.2009050530","article-title":"Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy","volume":"21","author":"Krupa","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jcjd.2013.06.001","article-title":"Molecular mechanisms linking diabetes to the accelerated development ofatherosclerosis","volume":"37","author":"Zeadin","year":"2013","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.biopha.2023.114252_bib48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","article-title":"Role of advanced glycation end products in cellular signaling","volume":"2","author":"Ott","year":"2014","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2023.114252_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/nu11081748","article-title":"The modern western diet rich in advanced glycation end-products (AGEs): an overview of its impact on obesity and early progression of renal pathology","volume":"11","author":"Bettiga","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2023.114252_bib50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114252_bib51","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2353\/ajpath.2009.090698","article-title":"Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy","volume":"175","author":"Kizu","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2023.114252_bib52","first-page":"839","article-title":"Production of cellulase from Bacillus species using cellulose from brewers spent grain (BSG) as sole carbon source, Asian J. Microbiol. Biotechnol","volume":"15","author":"Orji","year":"2013","journal-title":"Environ. Sci."},{"key":"10.1016\/j.biopha.2023.114252_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00441-011-1227-1","article-title":"The role of EMT in renal fibrosis","volume":"347","author":"Carew","year":"2012","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.biopha.2023.114252_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21070965","article-title":"Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer","volume":"21","author":"Du","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.114252_bib55","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/13880209.2019.1688843","article-title":"Curcumin alleviates diabetic nephropathy via inhibiting podocyte mesenchymal transdifferentiation and inducing autophagy in rats and MPC5 cells","volume":"57","author":"Tu","year":"2019","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.biopha.2023.114252_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-020-01854-3","article-title":"New insight into podocyte slit diaphragm, a therapeutic target of proteinuria","volume":"24","author":"Kawachi","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.kint.2020.09.027","article-title":"MAGI-2 orchestrates the localization of backbone proteins in the slit diaphragm of podocytes","volume":"99","author":"Yamada","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.biopha.2023.114252_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00428-007-0482-8","article-title":"Epithelial-mesenchymal transition (EMT) of renal tubular cells in canine glomerulonephritis","volume":"451","author":"Aresu","year":"2007","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2023.114252_bib59","first-page":"1","article-title":"Trimetazidine inhibits renal tubular epithelial cells to mesenchymal transition in diabetic rats via upregulation of Sirt1","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2023.114252_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ncrna4020014","article-title":"Functional role of non-coding RNAs during epithelial-to-mesenchymal transition","volume":"4","author":"Exp\u00f3sito-Vill\u00e9n","year":"2018","journal-title":"Non-Coding RNA"},{"key":"10.1016\/j.biopha.2023.114252_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-mesenchymal transition in cancer: a historical overview","volume":"13","author":"Ribatti","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2023.114252_bib62","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11684-018-0656-6","article-title":"Epithelial-to-mesenchymal transition in cancer: complexity and opportunities","volume":"12","author":"Zhang","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib63","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1152\/ajprenal.90500.2008","article-title":"C-peptide reverses TGF-\u03b21-induced changes in renal proximal tubular cells: Implications for treatment of diabetic nephropathy","volume":"296","author":"Hills","year":"2009","journal-title":"Am. J. Physiol. - Ren. Physiol."},{"key":"10.1016\/j.biopha.2023.114252_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/19336918.2015.1016686","article-title":"A new role for the PI3K\/Akt signaling pathway in the epithelial-mesenchymal transition","volume":"9","author":"Xu","year":"2015","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.biopha.2023.114252_bib65","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s11255-020-02545-4","article-title":"Autophagy in diabetic nephropathy: a review","volume":"52","author":"Koch","year":"2020","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00018-017-2639-1","article-title":"Autophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential","volume":"75","author":"Yang","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"2017","key":"10.1016\/j.biopha.2023.114252_bib67","article-title":"Research progress on mechanism of podocyte depletion in diabetic nephropathy","author":"Dai","year":"2017","journal-title":"J. Diabetes Res"},{"key":"10.1016\/j.biopha.2023.114252_bib68","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/0886022X.2017.1313164","article-title":"Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update","volume":"39","author":"Ying","year":"2017","journal-title":"Ren. Fail."},{"key":"10.1016\/j.biopha.2023.114252_bib69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.freeradbiomed.2017.12.040","article-title":"Diabetic nephropathy: Is there a role for oxidative stress","volume":"116","author":"Sagoo","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.135re9","article-title":"Alternative Wnt signaling is initiated by distinct receptors","volume":"1","author":"Van Amerongen","year":"2008","journal-title":"Sci. Signal."},{"key":"10.1016\/j.biopha.2023.114252_bib71","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/QAD.0b013e32833dbc31","article-title":"Activation of Notch signaling pathway in HIV-associated nephropathy","volume":"24","author":"Sharma","year":"2010","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2023.114252_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.468","article-title":"Emerging roles of exosomal miRNAs in diabetes mellitus","volume":"11","author":"He","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib73","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bcp.2018.06.017","article-title":"MicroRNA: a new generation therapeutic target in diabetic nephropathy","volume":"155","author":"Dewanjee","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114252_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118728","article-title":"LncRNA-antisense non-coding RNA in the INK4 locus promotes pyroptosis via miR-497\/thioredoxin-interacting protein axis in diabetic nephropathy","volume":"264","author":"Wang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.114252_bib75","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.yexcr.2016.12.006","article-title":"Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy","volume":"350","author":"Li","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2023.114252_bib76","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40618-020-01401-7","article-title":"MiR-21-5p in macrophage-derived extracellular vesicles affects podocyte pyroptosis in diabetic nephropathy by regulating A20","volume":"44","author":"Ding","year":"2021","journal-title":"J. Endocrinol. Invest"},{"key":"10.1016\/j.biopha.2023.114252_bib77","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1515\/med-2021-0328","article-title":"Long noncoding RNA MIAT inhibits the progression of diabetic nephropathy and the activation of NF-\u03baB pathway in high glucose-treated renal tubular epithelial cells by the miR-182-5p\/GPRC5A axis","volume":"16","author":"Dong","year":"2021","journal-title":"Open Med"},{"key":"10.1016\/j.biopha.2023.114252_bib78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/13813455.2019.1673431","article-title":"Long-chain non-coding RNA UCA1 inhibits renal tubular epithelial cell apoptosis by targeting microRNA-206 in diabetic nephropathy","volume":"128","author":"Yu","year":"2022","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2023.114252_bib79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00125-008-1184-8","article-title":"Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial","volume":"52","author":"Schjoedt","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2023.114252_bib80","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/HJH.0b013e32835bf7b0","article-title":"Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: Results of the ONTARGET trial","volume":"31","author":"Mann","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2023.114252_bib81","first-page":"170","article-title":"Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction","volume":"123","author":"Pan","year":"2015","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.biopha.2023.114252_bib82","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2337\/dc16-0795","article-title":"Long-term effect of losartan on kidney disease in American Indians with type 2 diabetes: a follow-up analysis of a randomized clinical trial","volume":"39","author":"Tanamas","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2023.114252_bib83","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2023.114252_bib84","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib85","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2215\/CJN.15260920","article-title":"Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis","volume":"16","author":"Jardine","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.08980621","article-title":"Potential effects of elimination of the black race coefficient in eGFR calculations in the CREDENCE trial","volume":"17","author":"Charytan","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib87","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results from the randomized CREDENCE trial","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.114252_bib88","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial","volume":"233","author":"Sarraju","year":"2021","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2023.114252_bib89","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including Those with HbA1c <7%: results from the CREDENCE trial","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.114252_bib90","first-page":"1545","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis","volume":"52","author":"Zhou","year":"2021"},{"key":"10.1016\/j.biopha.2023.114252_bib91","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib92","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2023.114252_bib93","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2023.114252_bib94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib95","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.114252_bib96","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib97","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2023.114252_bib98","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.114252_bib99","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib100","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107701","article-title":"Mineralocorticoid receptor antagonists in patients with chronic kidney disease","volume":"219","author":"Cosimato","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2023.114252_bib102","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000371497","article-title":"Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy","volume":"40","author":"Ruilope","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib103","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2023.114252_bib104","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.114252_bib106","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib107","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2023.114252_bib108","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose\u2013response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(98)09423-9","article-title":"Endothelin antagonists","volume":"353","author":"Benigni","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114252_bib110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bcp.12064","article-title":"Endothelin antagonists for diabetic and non-diabetic chronic kidney disease","volume":"76","author":"Kohan","year":"2013","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.114252_bib111","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib112","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.clinthera.2017.07.011","article-title":"Relationship between atrasentan concentrations and urinary albumin to creatinine ratio in western and japanese patients with diabetic nephropathy","volume":"40","author":"Lin","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2023.114252_bib113","first-page":"1937","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019"},{"key":"10.1016\/j.biopha.2023.114252_bib114","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cpt.2143","article-title":"Individual atrasentan exposure is associated with long-term kidney and heart failure outcomes in patients with type 2 diabetes and chronic kidney disease","volume":"109","author":"Koomen","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2023.114252_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104391","article-title":"More than just an enzyme: dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling","volume":"147","author":"Gupta","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2023.114252_bib116","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7382620","article-title":"Effect of dipeptidyl peptidase-4 (DPP-4) inhibition on biomarkers of kidney injury and vascular calcification in diabetic kidney disease: a randomized controlled trial","volume":"2021","author":"Trakarnvanich","year":"2021","journal-title":"J. Diabetes Res"},{"key":"10.1016\/j.biopha.2023.114252_bib117","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/ajprenal.00016.2008","article-title":"MCP-1\/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy","volume":"294","author":"Tesch","year":"2008","journal-title":"Am. J. Physiol. - Ren. Physiol."},{"key":"10.1016\/j.biopha.2023.114252_bib118","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2023.114252_bib119","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jdiacomp.2010.09.003","article-title":"Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results","volume":"25","author":"Navarro-Gonz\u00e1lez","year":"2011","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.biopha.2023.114252_bib120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib121","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/08860221003602645","article-title":"Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy","volume":"32","author":"Roozbeh","year":"2010","journal-title":"Ren. Fail."},{"key":"10.1016\/j.biopha.2023.114252_bib122","article-title":"A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy","volume":"3","author":"Beddhu","year":"2016","journal-title":"Can. J. Kidney Heal. Dis."},{"key":"10.1016\/j.biopha.2023.114252_bib123","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.34067\/KID.0001672021","article-title":"A non-purine xanthine oxidoreductase inhibitor reduces albuminuria in patients with DKD: a randomized controlled trial","volume":"2","author":"Bakris","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.biopha.2023.114252_bib124","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/0886022X.2021.1892759","article-title":"The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study","volume":"43","author":"Li","year":"2021","journal-title":"Ren. Fail."},{"key":"10.1016\/j.biopha.2023.114252_bib125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114252_bib126","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.ajkd.2007.09.005","article-title":"A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease","volume":"50","author":"Sinsakul","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.biopha.2023.114252_bib127","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0032-1314836","article-title":"Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy","volume":"44","author":"Pistrosch","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.biopha.2023.114252_bib128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib129","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ekir.2018.07.010","article-title":"Effect of PF-04634817, an oral ccr2\/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy","volume":"3","author":"Gale","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.biopha.2023.114252_bib130","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1053\/j.ajkd.2011.06.020","article-title":"Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial","volume":"58","author":"Lewis","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.biopha.2023.114252_bib131","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.08410520","article-title":"Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease a randomized placebo-controlled clinical trial","volume":"16","author":"Hanrahan","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01852-y","article-title":"Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis","volume":"11","author":"Xiang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biopha.2023.114252_bib133","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/stem.3375","article-title":"Mitochondrial transfer from mesenchymal stem cells to macrophages restricts inflammation and alleviates kidney injury in diabetic nephropathy mice via PGC-1\u03b1 activation","volume":"39","author":"Yuan","year":"2021","journal-title":"Stem Cells"},{"key":"10.1016\/j.biopha.2023.114252_bib134","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jcyt.2021.09.015","article-title":"Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up","volume":"24","author":"Wu","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biopha.2023.114252_bib135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","article-title":"Allogeneic mesenchymal precursor cells (mpC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study","volume":"12","author":"Packham","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2023.114252_bib136","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000520231","article-title":"Novel renal autologous cell therapy for type 2 diabetes mellitus chronic diabetic kidney disease: clinical trial design","author":"Stavas","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib137","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1681\/ASN.2019101029","article-title":"Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A","volume":"31","author":"Li","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2020)","key":"10.1016\/j.biopha.2023.114252_bib138","article-title":"Short-chain fatty acids ameliorate diabetic nephropathy via GPR43-mediated inhibition of oxidative stress and NF- \u03ba B signaling","author":"Huang","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2023.114252_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu14102148","article-title":"Association of dietary fish and n-3 unsaturated fatty acid consumption with diabetic nephropathy from a district hospital in northern Taiwan","volume":"14","author":"Lin","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2023.114252_bib140","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.1002\/jcp.27450","article-title":"Active vitamin D regulates macrophage M1\/M2 phenotypes via the STAT-1-TREM-1 pathway in diabetic nephropathy","volume":"234","author":"Zhang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2023.114252_bib141","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/08860220701569846","article-title":"Early renal injury induced by caffeine consumption in obese, diabetic ZSF1 rats","volume":"29","author":"Tofovic","year":"2007","journal-title":"Ren. Fail."},{"key":"10.1016\/j.biopha.2023.114252_bib142","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40618-019-01103-9","article-title":"Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis","volume":"43","author":"Dorsey-Trevi\u00f1o","year":"2020","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.biopha.2023.114252_bib143","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114252_bib144","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneph.2017.142","article-title":"Modelling diabetic nephropathy in mice","volume":"14","author":"Azushima","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2023.114252_bib145","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjms.2017.12.015","article-title":"Beneficial effects of pentoxifylline plus losartan dual therapy in type 2 diabetes with nephropathy","volume":"355","author":"Rabizadeh","year":"2018","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.biopha.2023.114252_bib146","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ndt\/gfv377","article-title":"Oleanolic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model","volume":"31","author":"Lee","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2023.114252_bib147","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.2147\/DDDT.S171286","article-title":"Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-\u03b21\/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy","volume":"12","author":"Du","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2023.114252_bib148","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:42:17Z","timestamp":1773387737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223000409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":148,"alternative-id":["S0753332223000409"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114252","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114252"}}